Read by QxMD icon Read

Journal of Clinical Endocrinology and Metabolism

Hui Wang, Jian Kuang, Mingtong Xu, Zhengnan Gao, Qifu Li, Shiping Liu, Fan Zhang, Yerong Yu, Zhen Liang, Weigang Zhao, Gangyi Yang, Ling Li, Yang Wang, Guangwei Li
Context: Although several studies suggest that improved β-cell function is a key determinant of glycemic remission in type 2 diabetes, other predictors remain unclear. Objective: The aim of this clamp-based study was to identify predictors of 2-year glycemic remission after short-term intensive insulin treatment. Design: A 2-year follow-up was planned in 124 drug-naïve type 2 diabetic patients who received continuous subcutaneous insulin infusion (CSII) for 2 weeks...
January 9, 2019: Journal of Clinical Endocrinology and Metabolism
Feitong Wu, Markus Juonala, Katja Pahkala, Marie-Jeanne Buscot, Matthew A Sabin, Niina Pitkänen, Tapani Rönnemaa, Antti Jula, Terho Lehtimäki, Nina Hutri-Kähönen, Mika Kähönen, Tomi Laitinen, Jorma S A Viikari, Olli T Raitakari, Costan G Magnussen
Context: No previous studies have examined the role of youth calcium intake in the development of impaired glucose metabolism, particularly those with long-term high calcium intake. Objectives: To examine whether youth and long-term (between youth and adulthood) dietary calcium intake is associated with adult impaired glucose metabolism and T2D. Design, Setting, and Participants: The Cardiovascular Risk in Young Finns Study (YFS) is a 31-year prospective cohort study (n=1134, aged 3-18 years at baseline)...
January 9, 2019: Journal of Clinical Endocrinology and Metabolism
Husam Ghanim, Sandeep Dhindsa, Manav Batra, Kelly Green, Sanaa Abuaysheh, Nitesh D Kuhadiya, Antoine Makdissi, Ajay Chaudhuri, Paresh Dandona
Context: Basic Fibroblast growth factor (FGF2) is an important stimulatory modulator of satellite cells in the skeletal muscle, which play a cardinal role in muscle growth and repair. Objective: We evaluated whether the skeletal muscle expression of FGF2 and muscle growth and differentiation factors are reduced in patients with hypogonadotropic hypogonadism (HH), and whether testosterone replacement therapy results in their restoration. Design: This is a secondary analysis of a previously completed trial of testosterone replacement in men with type 2 diabetes and HH...
January 9, 2019: Journal of Clinical Endocrinology and Metabolism
Dongyun Zhang, Jennifer S Way, Xinhai Zhang, Mareninov Sergey, Marvin Bergsneider, Marilene B Wang, William H Yong, Anthony P Heaney
Context: Aggressive prolactin-secreting pituitary adenomas that are resistant to conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic challenge. The mTOR inhibitor everolimus is approved to treat neuroendocrine tumors (NETs) and co-treatment with the somatostatin receptor ligand octreotide improved median progression free survival in patients with metastatic pancreatic NETs. Case Description: We describe off-label everolimus treatment of a prolactinoma (PRLoma) refractory to cabergoline, repeat surgical resection and radiation therapy...
January 8, 2019: Journal of Clinical Endocrinology and Metabolism
Aaliyah Riccardi, Tori Aspir, Lilia Shen, Chia-Ling Kuo, Taylor C Brown, Reju Korah, Timothy D Murtha, Justin Bellizzi, Kourosh Parham, Tobias Carling, Jessica Costa-Guda, Andrew Arnold
Context: Sporadic, solitary parathyroid adenoma is the commonest cause of primary hyperparathyroidism (PHPT). Apart from germline variants in certain cyclin dependent kinase inhibitor genes, and occasionally in MEN1, CASR, or CDC73, little is known about possible genetic variants in the population that may confer increased risk for development of typical sporadic adenoma. Transcriptionally-activating germline variants, especially within in the C-terminal conserved inhibitory domain (CCID), of GCM2, encoding a transcription factor required for parathyroid gland development, have recently been reported in association with familial and sporadic PHPT...
January 8, 2019: Journal of Clinical Endocrinology and Metabolism
Victor W Zhong, Juhaeri Juhaeri, Stephen R Cole, Christina M Shay, Penny Gordon-Larsen, Evangelos Kontopantelis, Elizabeth J Mayer-Davis
Context: HbA1C is an important predictor of severe hypoglycemia. Objective: To determine the association of proximal HbA1C level with first hypoglycemia requiring hospitalization (HH) in adults with incident type 2 diabetes (T2D). Design, Setting, and Participants: A nested case-control study was designed using linked data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England in 1997-2014. The first hypoglycemia as primary diagnosis for hospitalization after T2D diagnosis was identified...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Jerilynn C Prior
Background: Although the 2017 Endocrine Society Guidelines for gender dysphoria stipulated that cross-sex hormone therapy (CHT) achieve gonadal steroid levels equivalent to those of a cis-person of the chosen sex, for transwomen (male-to-female gender dysphoria) current gonadal therapy is usually estradiol. Accumulated evidence indicates that normally ovulatory menstrual cycles are necessary for ciswomen's current fertility as well as for later life bone and cardiovascular health and the prevention of breast and endometrial cancers...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Soma Saha, Ravinder Goswami
Context: Patients with hypoparathyroidism are managed with vitamin D and calcium. PTH is an emerging option due to its physiological action. Therefore, it is important to assess the efficacy and shortcomings of conventional therapy. Objective: We assessed the efficacy and safety of alfacalcidol in a large cohort of patients with idiopathic hypoparathyroidism (IH) and identified a subset that could be managed without oral calcium. Design and setting: Observational study at tertiary-care center...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Jakob Skov, Anders Sundström, Jonas F Ludvigsson, Olle Kämpe, Sophie Bensing
Context: Little is known of cardiovascular disease (CVD) in autoimmune Addison's disease (AAD). Inadequate glucocorticoid replacement may potentially increase the risk of CVD. Objective: To examine CVD in AAD, in subgroups of ischemic heart disease and cerebrovascular disease, and to investigate the effects of glucocorticoid and mineralocorticoid dosing. Design, Setting and patients: In this cohort-control study, we used Swedish health registries from 1964 to 2013 to identify 1,500 subjects with AAD and 13,758 matched controls...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Victoria Nisenblat, David J Sharkey, Zhao Wang, Susan F Evans, Martin Healey, E Maria C Ohlsson Teague, Cristin G Print, Sarah A Robertson, M Louise Hull
Context: Despite extensive searches for novel non-invasive diagnostics, laparoscopy remains the reference test for endometriosis. Circulating microRNAs (miRNAs) are purported endometriosis biomarkers however, the miRNA species and their diagnostic accuracy differ between studies and haven't been validated in independent cohorts. Objective: Identify endometriosis-specific plasma miRNAs and determine their diagnostic test accuracy. Setting: Two university-based, public hospitals and a private gynaecology practice in Australia...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Eva C Coopmans, Ammar Muhammad, Aart-Jan van der Lely, Joseph A M J L Janssen, Sebastian J C M M Neggers
Context: Pasireotide long-acting release (LAR) is a somatostatin multi-receptor ligand and in the current consensus criteria pasireotide LAR is considered the second-line medical treatment of acromegaly. We present in this paper our recommendations to define the position of pasireotide LAR in the treatment of acromegaly and provide recommendations for the management of pasireotide-induced hyperglycemia. Evidence acquisition: Our recommendations are based on our experiences with the pasireotide LAR and pegvisomant (PEGV) combination study and the available basic or clinical papers published in peer-reviewed international journals on pasireotide LAR and acromegaly...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Georgiana Sitoris, Flora Veltri, Pierre Kleynen, Julie Belhomme, Serge Rozenberg, Kris Poppe
Context/Objective: Targeted screening with high-risk case finding is proposed for the detection of thyroid dysfunction in pregnant women rather than universal screening (US). To determine the detection rate of subclinical and overt hypothyroidism (SCH/OH) based on American Thyroid Association guidelines (ATA-GL) criteria, and if it could be improved? Design, Setting, Participants: Cross-sectional study in 1832 pregnant women in a single centre. Thyroid function (TSH and free T4) and iron status was determined...
January 3, 2019: Journal of Clinical Endocrinology and Metabolism
Bruna L Freire, Thais K Homma, Mariana F A Funari, Antônio M Lerario, Gabriela A Vasques, Alexsandra C Malaquias, Ivo J P Arnhold, Alexander A L Jorge
Context: Patients born small for gestational age (SGA) who present with persistent short stature may have an underlying genetic etiology which accounts for prenatal and postnatal growth impairment. We have applied a unique massive parallel sequencing approach in cohort of exclusively nonsyndromic SGA patients to simultaneously interrogate for clinically significant genetic variants. Objective: To perform a genetic investigation of children with isolated short stature born SGA...
January 2, 2019: Journal of Clinical Endocrinology and Metabolism
D M van Velzen, A Paldino, M Klaver, N M Nota, J Defreyne, G K Hovingh, A Thijs, S Simsek, G T'Sjoen, M den Heijer
Context: The impact of gender affirming hormone therapy on cardiometabolic parameters is largely unknown. Objective: We assessed whether treatment with one year of oral or transdermal administration of estrogen (+ cyproterone) and transdermal or intramuscular application of testosterone have an impact on serum lipids levels and blood pressure. Design: and method This prospective observational study was conducted as a sub-study in the European Network for the Investigation of Gender Incongruence (ENIGI)...
January 2, 2019: Journal of Clinical Endocrinology and Metabolism
Lan Hainan, Wei Li, Ruonan Li, Xin Zheng, Gan Luo
Context: Pegvisomant, a growth hormone receptor (GHR) antagonist, is a well-known drug that was designed to treat acromegaly. However, recent studies have indicated that the GHR is a "moonlighting" protein that may exhibit dual functions based on its localization in the plasma membrane and nucleus. In light of this finding, we explored whether pegvisomant is a potential "moonlighting" GHR antagonist. In addition, the mechanisms of the endocytosis, post-endocytic sorting and degradation of pegvisomant are not fully understood...
December 31, 2018: Journal of Clinical Endocrinology and Metabolism
Ada S Cheung, Christopher Cunningham, Dong-Kyoon Daniel Ko, Vivian Ly, Hans Gray, Rudolf Hoermann, Boyd J G Strauss, Ebrahim Bani Hassan, Gustavo Duque, Peter Ebeling, Marcus G Pandy, Jeffrey D Zajac, Mathis Grossmann
Context: Androgen deprivation therapy (ADT) for prostate cancer (PCa) leads to a selective loss of leg muscle function during walking. Rodent models of ADT demonstrate that levator ani is exquisitely androgen sensitive. Objective: To determine whether the high androgen responsiveness of the levator ani muscle documented in rodents is evolutionarily conserved, and ADT is associated with a selective loss in leg muscle volumes. Design: Prospective longitudinal case-control study...
December 31, 2018: Journal of Clinical Endocrinology and Metabolism
Christina Tatsi, Nathan Pankratz, John Lane, Fabio R Faucz, Laura C Hernández-Ramírez, Margaret Keil, Giampaolo Trivellin, Prashant Chittiboina, James L Mills, Constantine A Stratakis, Maya B Lodish
Context: Genomic losses/gains are associated with cancer progression and prognosis. In pituitary adenomas, analyses of copy number variations (CNVs) have shown that a subset of adenomas shows higher genomic variability. However, whether CNVs are associated with tumor aggressiveness and prognosis has not been determined. Objective: We hypothesized that somatic CNVs of pituitary tumors may play a role in the progression and aggressiveness of pituitary corticotropinomas in children and adolescents...
December 28, 2018: Journal of Clinical Endocrinology and Metabolism
Rossella Elisei, Antonio Matrone, Laura Valerio, Eleonora Molinaro, Laura Agate, Valeria Bottici, David Viola, Carlotta Giani, Virginia Cappagli, Francesco Latrofa, Gabriele Materazzi, Liborio Torregrossa, Clara Ugolini, Fulvio Basolo, Cristina Romei
Background: Multiple Endocrine Neoplasia type 2B (MEN 2B) is a very rare syndrome characterized by a very peculiar phenotype with mucosal neuromas, marfanoid habitus and bumpy lips associated with medullary thyroid cancer (MTC) and pheocromocytoma (PHEO). Although the syndrome was first described 50 years ago, patients are still diagnosed too late when the MTC is metastatic and, frequently, when the PHEO was already developed. Cases presentation: We report on 2 cases of MEN 2B that were diagnosed too late, and this delay prevented their cure...
December 28, 2018: Journal of Clinical Endocrinology and Metabolism
Alissa A Newman, Nathan C Grimm, Jesse R Wilburn, Hayden M Schoenberg, S Raj J Trikha, Gary J Luckasen, Laurie M Biela, Christopher L Melby, Christopher Bell
CONTEXT: The combination of two beneficial anti-diabetes interventions, regular exercise and pharmaceuticals, is intuitively appealing. However, Metformin, the most commonly prescribed diabetes medication, attenuates the favorable physiological adaptations to exercise; in turn, exercise may impede the action of metformin. OBJECTIVE: We sought to determine the influence of an alternative diabetes treatment, sodium glucose co-transporter 2 (SGLT2) inhibition, on the response to endurance exercise training...
December 28, 2018: Journal of Clinical Endocrinology and Metabolism
Gabrielle Page-Wilson, Jane B Peters, Sunil K Panigrahi, Thomas P Jacobs, Judith Korner, Marc Otten, Jeffrey N Bruce, Sharon L Wardlaw
Context: Glucocorticoids regulate energy balance, in part by stimulating the orexigenic neuropeptide agouti-related protein (AgRP). AgRP neurons express glucocorticoid receptors and glucocorticoids have been shown to stimulate AgRP gene expression in rodents. Objective: We sought to determine if there is a relationship between plasma AgRP and hypothalamic AgRP in rats and to evaluate the relationship between cortisol and plasma AgRP in humans. Methods: We retrospectively evaluated plasma AgRP levels prior to transsphenoidal surgery in 31 CD patients vs...
December 28, 2018: Journal of Clinical Endocrinology and Metabolism
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"